Get the Stockscreener App
2.54
4.96%
0.12
Pre-market:
2.54
Xenetic Biosciences Inc stock is traded at $2.54, with a volume of 11,594.
It is up +4.96% in the last 24 hours and down -10.88% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$2.42
Open:
$2.42
24h Volume:
11,594
Relative Volume:
0.01
Market Cap:
$5.82M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-0.9236
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-1.55%
1M Performance:
-10.88%
6M Performance:
-17.28%
1Y Performance:
-43.93%
1-Day Range:
$2.36
$2.54
1-Week Range:
$2.31
$2.7208
52-Week Range:
$2.20
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.54 | 5.54M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Will Xenetic Biosciences Inc. stock keep outperforming rivals2025 Buyback Activity & Risk Controlled Stock Alerts - Newser
Is Xenetic Biosciences Inc. (3XB0) stock a top hedge fund pick2025 Top Gainers & Reliable Volume Spike Trade Alerts - Newser
Is Xenetic Biosciences Inc. (3XB0) stock a buy for dividend portfoliosWeekly Stock Report & Real-Time Sentiment Analysis - Newser
Xenetic Biosciences, Inc. (XBIO) Jumps 10% in Pre-market: What’s Driving the Move? - Stocks Telegraph
Can Xenetic Biosciences Inc. (3XB0) stock reach $200 price targetJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Is Xenetic Biosciences Inc. (3XB0) stock a fit for income portfoliosEarnings Beat & Technical Pattern Alert System - Newser
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Courier & Press
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Times Record News
Is Xenetic Biosciences Inc. (3XB0) stock bottoming after sell offWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
Xenetic Biosciences (XBIO) Stock Analysis Report | Financials & Insights - Benzinga
What analysts say about Xenetic Biosciences Inc stockPortfolio Diversification Tips & Exceptional Profit Trading - earlytimes.in
Published on: 2025-11-28 02:47:25 - BỘ NỘI VỤ
Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Xenetic Biosciences Inc. (3XB0) stock prepared for digital transitionJuly 2025 Selloffs & Trade Opportunity Analysis Reports - newser.com
How Xenetic Biosciences Inc. (3XB0) stock reacts to weak economyJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - newser.com
Is Xenetic Biosciences Inc. forming a reversal patternJuly 2025 Rallies & Safe Capital Allocation Plans - newser.com
Is Xenetic Biosciences Inc. stock bottoming outJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Long term hold vs stop loss in Xenetic Biosciences Inc.Quarterly Performance Summary & Expert-Curated Trade Recommendations - newser.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Xenetic Biosciences extends collaboration with Scripps Research By Investing.com - Investing.com Nigeria
What hedge fund activity signals for Xenetic Biosciences Inc. stock - newser.com
Xenetic Biosciences extends collaboration with Scripps Research - Investing.com
Xenetic (XBIO) Extends Collaboration With Scripps to Boost Cance - GuruFocus
Xenetic Biosciences (NASDAQ: XBIO) extends 4-month Scripps DNase I CAR-T collaboration toward Phase 1 - Stock Titan
Will Xenetic Biosciences Inc. stock split attract more investorsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):